Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40-50%) and BRAF (10%)<sup>1</sup>, inhibition of this pathway typically drives resistance clinically. This evidence concerns the gene KRAS and colorectal carcinoma.